Avectas is transforming how cell therapies are manufactured, enabling the seamless transition from development to clinic to commercial scale manufacturing.
For autologous cell therapy, the typical transition in manufacturing process from development to clinical manufacture is costly, time consuming and complex.
For commercial manufacturing, the challenge is magnified further adding more time, cost and risk. The impact is too few patients can access cell therapies.
SoluScale is the solution to scaling-up and scaling-out cell therapies.
SoluScale’s closed single use Cell Chamber (SCC) holds the entire product-contact fluid path.The compact automated manufacturing unit (AMU), runs the process within it. The AMU enables Activation, Transduction, Expansion and Harvest in one closed system, with a digital run record for each batch.
Therapeutic developers can begin with the SCC at the bench, move into a single AMU, then into a high-density array of AMUs under centralized supervision depending on capacity need.
The SoluScale platform is built on more than a decade of cell-engineering expertise, including our work on non-viral delivery based on Solupore transfection technology, including in vivo studies, which has been published in peer-reviewed journals including PLOS ONE, Cytotherapy and Molecular Therapy.
SoluScale has been evaluated by independent partners across the US and Europe, and guided by a Scientific Advisory Board comprising Prof. Bruce Levine (University of Pennsylvania), Prof. Mark Lowdell (University College London) and Prof. Evren Alici (Karolinska Institutet).
Based in Dublin and Boston, we work with CDMOs, therapy developers and research organisations to move from research to patients, simpler, faster and more economical.
Find out more about our Vector-free intracellular delivery by reversible permeabilization.
Download
Find out more about a novel non-viral delivery method that enables efficient engineering of primary human T cells for ex vivo cell therapy applications.
Download
Increased functional potency of multi-edited CAR-T cells manufactured by a non-viral transfection system.
DownloadExecutive Leadership Team
Dr. Michael Maguire
Chief Executive Officer, Board Member
Biomedical engineer and co-founder of Avectas leading the development and commercialisation of the SoluScale TM platform.
Dr. Ann Brady
Chief Business Officer, Board Member
Seasoned life sciences executive with extensive experience in business development, alliance management and corporate strategy.
Eoin Heffernan, ACA
Vice President, Finance & Strategy,
Secretary to the Board
Chartered accountant leading finance, strategic planning and operations across Avectas.
Board of Directors (Non-Executive)
Eunan Maguire
Chair of the Board
Senior investment professional and board leader with experience across venture capital, corporate finance and biotech governance.
Barry Leonard
Non-Executive Director
Biotech executive and board member bringing strategic guidance and governance experience.
Dr. Mary Martin
Non-Executive Director
Seasoned biopharma leader and board director with deep R&D and corporate leadership expertise.
Scientific Advisory Board
Prof. Bruce L. Levine
Scientific Advisor
Barbara & Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania, pioneer in CAR-T development.
Prof. Mark Lowdell
Scientific Advisor
Immunologist and cell therapy pioneer with extensive GMP and potency analytics expertise.
Prof. Evren Alici
Scientific Advisor
Clinician-scientist in immuno-oncology and engineered immune cells, advising on clinical strategy and cell phenotype.
